- Healthcare Morning Briefing - Oct 1Triple-agonist retatrutide shows notable benefits for people with type 2 diabetes, while policy shifts and insurer moves add pressure on hospitals and pharma. Read what you should watch today.
- Healthcare Wrap Sep 30: Access, Safety, InnovationToday's healthcare headlines balanced big research advances and regulatory moves against payer-driven access limits and safety concerns. Read on for what happened, how markets reacted, and what you should watch next.
- Healthcare Headlines and Policy Risks - Sep 30Today’s healthcare briefing balances tech and research wins with rising policy and legal risks. From wearable AI and simulated imaging to Medicaid eligibility changes and a high-profile biotech suit, here’s what you need to know.
- Healthcare Mixed Signals - Sep 29 WrapToday’s healthcare headlines mixed scientific advances, a $2.6B obesity deal and high-profile legal and policy moves. Read what moved markets and what you should watch next.
- Healthcare Mixed Signals: Kodiak, Policy, Research - Sep 29Kodiak's Phase 3 eye drug results lifted market value while blood-based immunotherapy research promises less invasive cancer care. Policy moves on Medicare and Medicaid create near-term uncertainty you should watch.
- Healthcare Sector Wrap Sep 28Biotech clinical wins and an FDA approval pushed momentum today, but policy and cost headwinds kept the picture mixed. Read what moved stocks, what matters next, and how you might watch risks.
- Healthcare Roundup: Vaccines, PBMs, GLP-1s - Sep 28A vaccine science breakthrough and continuing GLP-1 momentum face offsetting regulatory and security risks. Read what moved the sector overnight and what you should watch today.
- Healthcare Wrap: Trials, Surveillance, Policy - Sep 27Clinical wins on low-dose radiation and a new long COVID database offer promise, but HHS funding cuts and preparedness concerns temper optimism. Heading into Monday, watch policy catalysts.
- Healthcare: Policy Cuts, GLP-1 Data & Pandemic Prep - Sep 27A mixed picture for healthcare heading into the long weekend: regulatory pressure and funding cuts sit alongside fresh GLP-1 and pandemic preparedness moves. Read what you should watch when markets reopen Monday.
- Healthcare Wrap-Up Sep 26: Research vs PolicyToday’s healthcare headlines mixed big scientific gains with policy and commercial headwinds. Research on dementia, cardiac protein degradation, and cerebellum reward signals landed alongside HHS budget cuts and uneven biotech performance.
- Healthcare News Snapshot - Sep 26Lilly won FDA approval for a once‑weekly insulin as policy cuts and 340B scrutiny create headwinds. Research on cystic fibrosis, Powassan virus and VR therapy offers clinical upside.
- Healthcare: Lilly Approval and Policy Risks - Sep 25Today’s Healthcare wrap covers Eli Lilly’s FDA win for a once-weekly insulin, Roche sublicensing for pandemic prep, and fresh policy and hospital-care scrutiny. You’ll find market context, key implications, and what to watch next.
- Healthcare: IPOs, FDA Votes, and Public Health - Sep 25Biotech activity and regulatory signals lead today’s healthcare headlines, with a $446M RNAi IPO and FDA advisers backing a multicancer test alongside public health and policy risks. Here’s what you need to know for Sep 25.
- Healthcare: Merck Win, AI Costs, Policy Moves Sep 24Clinical wins and strategic deals punctuated a mixed day in healthcare. Trial success at Merck and more China deals met safety flags, AI cost warnings and regulatory developments.
- Healthcare Pulse: AI, FDA, Biotech Moves - Sep 24Biotech funding and an RNA win for kidney disease grabbed headlines, while policy and public-health stories remind you risks remain. Here’s what matters for traders and long-term investors today.
- Healthcare Sector Evening Wrap Sep 23Funding wins and RNA trial success offset policy headwinds and troubling public-health studies today. Read how CMS moves, Enveda's $311M raise and Roche/Ionis data could shape sector moves tomorrow.
- Healthcare Mixed Signals on Trials, Policy - Sep 23Biotech clinical wins and promising delivery tech sit alongside policy fights over remote monitoring and warnings about care capacity. Read what matters for your portfolio today.
- Healthcare Wrap-Up: Clinical Wins & Policy - Sep 22Amgen reported a Phase 3 victory and Viking posted encouraging maintenance data, while new global phage guidance and HHS animal-testing initiatives add regulatory clarity. Mixed safety signals and policy nuances mean selectivity will matter for your positions.
- Healthcare: FDA Wins, Coverage Pain - Sep 22FDA clears first disease-modifying drug for Alexander disease and Beacon posts pivotal success, while rising insurance costs and Medicaid debate create policy risk. Read what you need to watch today.
- Healthcare Rally on Approvals and Data - Sep 21Regulatory approvals, a pivotal gene therapy win and an FDA advisory trigger for a cancer test drove optimism across healthcare today. Partnerships on population molecular data and major pharma roadmaps kept momentum alive.
- Healthcare Snapshot: Novo Plans, GLP‑1 Readiness - Sep 21Novo Nordisk detailed a new obesity and DTC strategy while research on the gut microbiome and newborn attention advances science. System readiness, payment costs and AI in research are key themes.
- Healthcare Sector Wrap Sep 20Clinical wins in diagnostics and cell therapy contrasted with policy uncertainty over Medicaid drug pricing and insurance dealmaking. Read the key takeaways, what to watch, and how these items could shape the sector heading into Monday.
- Healthcare Briefing: Mixed Signals - Sep 20Infectious disease outbreaks and policy moves set mixed tones for healthcare heading into the long weekend. Corporate deals, a biotech trial pause, and rising medical debt are top items to watch.
- Healthcare Sector Strains Ahead - Sep 19A string of public-health warnings, a clinical trial pause and payer-policy shifts left the healthcare landscape looking riskier heading into the long weekend. Read what you should watch next.
- Healthcare Sector Mixed Signals - Sep 19A weekend roundup: state investments in rural health and an Ascension-Aetna deal counterbalance biotech trial setbacks, telehealth access limits, and policy uncertainty around Medicaid drug discounts. Read what you should watch heading into Monday.
- Healthcare Mixed Signals - Sep 18 WrapBiotech headlines drove volatility Friday as Xenon paused a trial and Ultragenyx priced a newly approved gene therapy at $4M. You should watch regulatory updates, reimbursement moves, and telehealth access trends heading into next week.
- Healthcare: Science, Policy and IPOs - Sep 18Today’s healthcare mix includes major research breakthroughs, a $350M biotech IPO and policy pressure on Medicaid nutrition programs. You’ll want to weigh scientific upside against regulatory and fiscal risks.
- Healthcare Highlights and Risks - Sep 17Today’s healthcare news mixed clinical wins with governance and public‑health concerns. A new FDA gene therapy and a $1.4B pharma tie-up balanced AI safety warnings and widening care gaps.
- Healthcare R&D Momentum and Deals - Sep 17Roche's up-to-$1B bispecifics pact with Dualitas leads a slate of positive research results and a U.K. pricing win for AstraZeneca. Read what you should watch today as FDA hiring delays add a caveat.
- Healthcare Sector Mixed Signals - Sep 16AI deals, clinical wins and startup funding pushed innovation forward while lawsuits, system challenges and ethical questions kept risk squarely in view. Read our evening wrap to see what matters for your portfolio tomorrow.
- Healthcare Morning Briefing - Sep 16Today’s healthcare headlines mix promising diagnostics and cancer data with regulatory and public health risks. Read what to watch, from radioligand generics to rural health tech and policy shifts.
- Healthcare Sector Wrap - Sep 15Today brought a mix of policy, public-health alarms and innovation headlines: FDA's new early-drug pilot and Medicare tech expansion sit alongside measles deaths and calls for tighter equipment oversight. Read on for what moved the sector and what you'll want to watch tomorrow.
- Healthcare Roundup Sep 15Clinical wins in oncology clash with an AstraZeneca drug failure and policy headwinds in Medicaid and Medicare. Read what moved the sector overnight and what you should watch today.
- Healthcare Mixed Signals: AI Wins, Drug Setbacks - Sep 14Today’s healthcare action was a mixed bag: AI and infection-control studies delivered clear wins while drug trial failures, layoffs and a major settlement injected caution. Read what you should watch next.
- Healthcare Sector Mix: Research, Policy, AI - Sep 14Today’s healthcare headlines span a high-profile rebrand at Novo, fresh research on aortic stiffness and pollution risks, and operational strains in health systems and ambulatory care. Read what you should watch and how these themes could affect sector dynamics.
- Healthcare Mixed Signals - Sep 13Scientific advances and an FDA approval tempered by a high-profile trial miss and rising measles deaths. Heading into Monday, you'll want to watch biotech approvals, regulatory rulings, and public health developments closely.
- Healthcare: FDA Win, Drug Setback - Sep 13A major FDA approval and new federal AI funding provide momentum, but AstraZeneca's breast cancer trial miss and hospital transparency gaps temper the outlook. Read what you should watch heading into Monday.
- Healthcare Wrap Sep 12: FDA Win, AI Progress, Trial SetbackA mixed day for healthcare: Scholar Rock wins FDA approval while AstraZeneca reports a pivotal breast cancer trial miss. AI tools and ARPA-H funding push innovation, regulatory and compliance stories keep risks front and center.
- Healthcare: Clinical Wins Lead Sep 12Clinical data and a fresh FDA approval set a constructive tone for healthcare heading into the long weekend. Readouts in lung cancer, a Scholar Rock approval, and new AI funding are key items you should watch.
- Healthcare: AI, policy and diagnostics - Sep 11Today brought a mix of science and policy: Columbia researchers advanced blood/gene tests for early Alzheimer's timing, ARPA-H pledged $62M for agentic AI in heart care, while hospitals and Medicaid faced renewed regulatory scrutiny. You’ll want to track upcoming approvals, earnings and regulatory guidance.
- Healthcare Headwinds Mount - Sep 11Regulatory and clinical setbacks are shaping healthcare headlines this morning. From tougher Medicare Advantage thresholds to an FDA partial hold on Biohaven, here’s what you need to know for Sep 11.
- Healthcare: Trials, Policy Headwinds and CEO Moves - Sep 10Regulatory holds, tougher Medicare Advantage thresholds and drug trial disappointments weighed on sentiment, while new imaging tech and clinical research offered longer-term upside. Read what matters for your portfolio heading into tomorrow.
- Healthcare Morning Brief - Sep 10Mixed clinical news, policy rulings and public-health developments set a cautious tone for healthcare on Sep 10. Read how a biotech miss, rural access rulings and a new cancer study could shape stocks and policy.
- Healthcare Momentum: Discoveries, FDA Stability - Sep 9Breakthrough preclinical work on an oral Ebola blocker, ARPA-H’s $62.7M push for AI heart-failure tools, and permanent FDA leadership drove the tape. You’ll find what moved the sector and what to watch next.
- Healthcare Morning Brief - Sep 9Biotech trial wins and AI advances headline a mixed healthcare tape today. You’ll want to track regulatory signals, workforce stress, and AI integration as catalysts that could move names like $ROIV and $BMY.
- Healthcare Wrap-Up Sep 8: Mixed SignalsToday’s Healthcare session mixed scientific breakthroughs and financing wins with clinical and regulatory setbacks. Read what moved providers, biotechs and policy ahead of tomorrow’s catalysts.
- Healthcare Mixed Signals: Trials, Costs and Policy Risks - Sep 8A Roivant mid-stage win lifts clinical momentum, but access, cost and regulatory stories temper the upside. Today's briefing breaks down trial news, payer strategy, policy risks, and AI data themes.
- Healthcare Advances, Trial Setbacks - Sep 7Cedars-Sinai rolled out three research advances in genetics, anxiety measurement and the small bowel microbiome, while Novo Nordisk halted two cardiovascular trials and the ADA faces ongoing internal review. Markets were closed for Labor Day, making these headlines the focal points heading into trading on Sep 8.
- Healthcare: Trial Setback & New Research - Sep 7A late-stage cardiovascular trial disappointment with $NVS and $IONS contrasts with encouraging preclinical findings for a repurposed cancer drug and new cardiac care guidance. Markets were closed for Labor Day; here’s what you should watch heading into Sep 8.
- Healthcare Hit by Novartis Setback - Sep 6 WrapA pivotal Novartis/Ionis cardiovascular drug failed to reduce heart events despite lowering Lp(a), raising questions about the class and trial design. New data on coronary artery calcium and care-use studies add mixed signals heading into the long weekend.